San Francisco, United States
Scribe Biosciences is an early-stage company that is revolutionizing the biotechnology industry with its pioneering technologies. The company, founded in 2017 and headquartered in the United States, is committed to accelerating immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions. With the slogan "Study Single-Cell Interactions with Unprecedented Throughput and Precision," Scribe Biosciences is on a mission to offer unprecedented throughput and precision in the study of single-cell interactions.
The company recently secured a Non Equity Assistance investment on 06 June 2023, with BioTools Innovator being the contributing investor. This investment serves as a testament to the confidence that industry leaders have in Scribe Biosciences' innovative approach and potential impact in the biotechnology sector.
